1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Biosimilar (Insulin) - Competitive Landscape and Market & Pipeline Analysis, 2017

DelveInsight’s, “Biosimilar (Insulin) - Competitive Landscape and Market & Pipeline Analysis, 2017” discusses the global insulin biosimilar industry. Report analyzes that Insulin and Insulin Biosimilars holds a future scope and potential in the market. It highlights the market trends, regulatory requirements for US and EU and key domestic players.

Report provides an insight on Insulin Biosimilars that are under development for Type 1 and Type 2 Diabetes with an insight on the Epidemiology of the disease. It provides detailed information on the 11 Insulin Biosimilar that are in pipeline.

It analyses Insulin Biosimilar industry and discusses the key market trends, major players, market assessment of 6 marketed insulin and the types of insulin with the length activity available in market. Report provides an update on the recent collaborations occurring in the insulin biosimilar market and the companies looking for partnership for the same.

Scope:
- Coverage of global insulin biosimilar under development across the globe
- Sales forecast for marketed insulin from 2015 to 2017
- Detailed information on product description and related stage of development, the mode of therapy, mechanism of action, development partner and technology information.
- The report discusses the biosimilar regulatory landscape of various markets including developed markets of the US and EU
- Report analyses the types of insulin under development with respect to their market share and length of activity

Reason to Buy
- The insulin biosimilar report covers complete Pipeline intelligence and understanding over therapeutics development for insulin market.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of insulin under development
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding the insulin biosimilar pipeline in-depth
- Identifying the upcoming leaders in the insulin biosimilar market in the coming year

Table Of Contents

Biosimilar (Insulin) - Competitive Landscape and Market and Pipeline Analysis, 2017
Executive Summary
Biosimilar
History of Insulin and Insulin Biosimilar Development
Regulatory Pathways in US and EU
Illustration of the Originator and Biosimilar Development
Major Indication
Epidemology
Complications Associated with Diabetes
Diagnosis of Diabetes
Analysis
Clinical Trials
Technology
Market Assessment
Market Trends
Drivers
Barriers
Historical Sales Data for the Marketed Drugs
Forecasted Sales Data for the Marketed Drugs
Major Competitors
Types of insulin and length of activity
Pipeline Therapeutics
Therapeutics under Development by Companies
Therapeutic Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Dormant Products
Product Development Activities
Companies involved in Therapeutics Development

Appendix
Methodology
Consulting Services
About DelveInsight
Contact Us
Disclaimer

List of Tables
Table 1:Marketed Insulin Details, 2017
Table 8: Historical Global Sales of Marketed Insulin Analogs 2011-2014 (in million USD), 2017
Table 9: Forecasted Global Sales of Marketed Insulin Analogs 2015-2017 (in million USD), 2017
Table 10:Number of Products Under Development for Insulin Biosimilars,2017
Table 11: Number of Products under Development by Companies,2017
Table 12: Late Stage Products (Phase III and Filed), 2017
Table 13: Early Stage Products (Phase I and IND),2017
Table 14: Pre-Clinical and Discovery Products, 2017
Table 15: Assessment by Monotherapy Products, 2017
Table 16: Assessment by Combination Products, 2017
Table 17: Assessment by Route Of Administration, 2017
Table 18:Assessment by Stage and Route Of Administration, 2017
Table 19: Assessment by Molecule Type, 2017
Table 20: Assessment by Stage and Molecule Type, 2017
Table 21: Dormant Products, 2017

List of Figures
Figure 1: Number of products with ongoing and completed clinical trials, 2017
Figure 2: Number of products with ongoing and completed clinical trials, 2017
Figure 3: Number of products in clinical trials with companies, 2017
Figure 4: Number of technology associated with the companies, 2017
Figure 5: Number of Product with Insulin Biosimilar Technology, 2017
Figure 6: Historical Global Sales of Marketed Insulin Analogs 2011-2014 (in million USD), 2017
Figure 7: Forecasted Global Sales of Marketed Insulin Analogs 2015-2017 (in million USD), 2017
Figure 8: Types of Insulin Biosimilar Under Development, 2017
Figure 9: Number of different type of Insulin Biosimilar and Company, 2017
Figure 10: Number of Products under Development for Insulin Biosimilars, 2017
Figure 11: Late Stage Products (Phase III), 2017
Figure 12: Mid Stage Products (Phase II),2017
Figure 13: Early Stage Products (Phase I and IND), 2017
Figure 14:Pre-Clinical and Discovery Products, 2017
Figure 15: Assessment by Monotherapy Products, 2017
Figure 16: Assessment by Combination Products, 2017
Figure 17: Assessment by Route of Administration, 2017
Figure 18: Assessment by Stage and Route of Administration, 2017
Figure 19: Assessment by Molecule Type, 2017
Figure 20: Assessment by Stage and Molecule Type, 2017
Figure 21: Dormant Products, 2017

List of Companies
- Roche
- Bristol-Myers Squibb Company
- Sanofi
- Abbvie Inc
- Pfizer Inc
- Biosimilar
- Celltrion
- Oncobiologics, Inc.
- Richter-Helm BioTec GmbH and Co. KG

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Type 2 Diabetes Mellitus - GPCRs and Protein Kinases Dominate Pipeline, with Most Promising First-in-Class Targets Demonstrating Potential Disease-Modifying Effects

Frontier Pharma: Type 2 Diabetes Mellitus - GPCRs and Protein Kinases Dominate Pipeline, with Most Promising First-in-Class Targets Demonstrating Potential Disease-Modifying Effects

  • $ 6995
  • Industry report
  • December 2016
  • by GBI Research

Frontier Pharma: Type 2 Diabetes Mellitus - GPCRs and Protein Kinases Dominate Pipeline, with Most Promising First-in-Class Targets Demonstrating Potential Disease-Modifying Effects Summary Type 2 diabetes ...

Global Insulin Market - Industry Analysis and forecast (2017 - 2022)

Global Insulin Market - Industry Analysis and forecast (2017 - 2022)

  • $ 4250
  • Industry report
  • February 2017
  • by Mordor Intelligence LLP

The global insulin market is expected to reach USD 42 billion by 2020, growing at a CAGR of XX%. Insulin is a peptide hormone secreted by the beta cells in the pancreas. Insulin maintains the metabolism ...

Asia Insulin Market- analysis and Forecast (2017 - 2022)

Asia Insulin Market- analysis and Forecast (2017 - 2022)

  • $ 3850
  • Industry report
  • January 2017
  • by Mordor Intelligence LLP

Changing lifestyles, rapid urbanization and cheap calories in the form of processed foods are putting more and more people at risk of developing Type-2 diabetes in Asia. Despite having a lower body weight, ...


Download Unlimited Documents from Trusted Public Sources

Diabetes Statistics

  • March 2017
    10 pages
  • Diabetes  

    Therapy  

View report >

Hormone and Therapy Market in Pakistan and the US

  • March 2017
    7 pages
  • Hormone  

    Therapy  

    Diabetes  

  • Pakistan  

    United States  

View report >

Glucagon Like Peptide 1 Receptor Activator Market

  • March 2017
    3 pages
  • Glucagon Like P...  

    Antidiabetics  

    Cardiology  

View report >

Related Market Segments :

Insulin
Biosimilar

ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.